Cancer. Malignant neoplasms
Conditions
Interventions
Intervention 1: Patients in intervention group will be received bupropion sustained release (SR) (Abidi pharmaceutical, Tehran, Iran) 150 mg/day for 4 weeks. Intervention 2: Patients in control group
Treatment - Drugs
Placebo
Patients in intervention group will be received bupropion sustained release (SR) (Abidi pharmaceutical, Tehran, Iran) 150 mg/day for 4 weeks.
Patients in control group will be received placebo of bupropion sustained release (SR) (Abidi pharmaceutical, Tehran, Iran) 150 mg/day for 4 weeks.
Sponsors
Vice Chancellor for Research,Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria were at least 18 years old, having a diagnosis of cancer with survival expectancy greater than 6 months, having a cancer-related fatigue defined by a score 4 or more on a brief fatigue inventory (BFI) screening scale that ranged from 0 (none) to 10 (as bad as it can be), and hemoglobin more than 9 g/dl taken less than 4 weeks before enrollment. The exclusion criteria were Karnofsky Performance Scale of <50, history of convulsive seizure, current use (within 6 weeks preceding participation) of erythropoietin, psycho stimulants or antidepressants, brain metastasis, history of fatigue prior to cancer diagnosis, any medical cause for fatigue identified on screening tests or a review of systems, hypersensitivity to bupropion and illiteracy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Timepoint: Before intervention and after 4 weeks. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Before intervention and after 4 weeks. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Sarah Mousavi
Isfahan University of Medical Sciences
Outcome results
None listed